This condition may occur in any case of acquired liver failure, including severe hepatitis.
Liver damage can lead to the buildup of ammonia and other toxic materials in the body. This happens when the liver doesn't work properly to break down and eliminate these chemicals. The toxic materials can damage brain tissue.
Specific areas of the brain, such as the basal ganglia, are more likely to be injured from liver failure. The basal ganglia help control movement. This condition is the "Non-Wilsonian" type. This means that the liver damage is not caused by copper deposits in the liver, which is a key feature of Wilson's disease.
Treatment helps reduce the toxic chemicals that build up from liver failure. It may include antibiotics or a medication such as lactulose, which lowers the level of ammonia in the blood.
A treatment called branched-chain amino acid therapy may also improve symptoms and reverse brain damage from this condition.
There is no specific treatment for the neurologic syndrome, because it is caused by irreversible liver damage. A liver transplant may cure the liver disease. However, this operation may not reverse the symptoms of brain damage.
This is a long-term (chronic) condition that may lead to irreversible nervous system (neurological) symptoms.
The patient may continue to get worse and may die without a liver transplant. If a transplant is done early in the course of the disease, the neurological syndrome may be reversible.
Call your health care provider if you have any symptoms of liver disease.
It is not possible to prevent all forms of liver disease. However, alcoholic and viral hepatitis may be prevented.
To reduce your risk of getting alcoholic or viral hepatitis:
Avoid risky behaviors, such as IV drug use or unprotected sex.
Don't drink, or drink only in moderation.
Garcia-Tiso G. Cirrhosis and its sequellae. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 157.
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; George F. Longstreth, MD, Department of Gastroenterology, Kaiser Permanente Medical Care Program, San Diego, California. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.